Droperidol 5 mg IV Push Administration Protocol
Droperidol 5 mg IV should be administered as a slow intravenous push, not as a rapid bolus, with continuous monitoring of vital signs and ECG before, during, and after administration due to the risk of QT prolongation and hypotension.
Dosing and Administration Guidelines
The FDA-approved maximum recommended initial dose of droperidol is 2.5 mg IM or slow IV 1. A 5 mg dose exceeds this recommendation and should only be used when the potential benefit outweighs the risk, particularly in specific clinical scenarios like acute agitation where this dose has been studied 2.
Pre-Administration Requirements
Mandatory screening before any droperidol administration 3:
- ECG to measure QTc interval - Contraindicated if QTc >440 ms (males) or >450 ms (females)
- Vital signs baseline - Blood pressure, heart rate, respiratory rate
- Risk factor assessment for QT prolongation:
- Age ≥65 years
- Congestive heart failure history
- Bradycardia
- Diuretic use
- Cardiac hypertrophy
- Hypokalemia or hypomagnesemia
- Alcohol abuse
- Concurrent medications that prolong QT interval
Administration Technique
For 5 mg IV dose 2:
- Administer as slow IV push over several minutes (not rapid bolus)
- Continuous monitoring during administration
- Have resuscitation equipment immediately available
- Consider lower initial dose (2.5 mg) in elderly patients (>65 years) 4
Clinical Context for 5 mg Dosing
The 5 mg dose has been specifically studied and used in 2:
- Acute agitation/behavioral disturbance in emergency settings
- Difficult-to-sedate patients (alcoholics, chronic substance users) during procedures 3
- As adjunct therapy when first-line agents are unsuccessful
Important caveat: The 2006 emergency medicine guideline supports droperidol 5 mg for acute agitation as Level B evidence 2, but this must be balanced against the FDA black box warning requiring it be used "only when first-line drugs are unsuccessful" 3.
Post-Administration Monitoring
Continuous monitoring for at least 2-4 hours (duration of drug effect) 3:
- ECG monitoring - Watch for QT prolongation, arrhythmias
- Vital signs every 5-15 minutes initially:
- Sedation level assessment
- Extrapyramidal symptoms surveillance
Expected Onset and Duration
- Onset of action: 3-10 minutes 3
- Duration of effect: 2-4 hours 3
- Peak effect: Typically within 30 minutes 4
Adverse Event Management
Hypotension (most common complication) 3, 4:
- Reposition patient to improve venous return
- Volume expansion with IV fluids
- Avoid epinephrine - may paradoxically decrease blood pressure due to alpha-adrenergic blocking action of droperidol 1
- Consider other pressor agents if needed
Extrapyramidal symptoms/dystonia 3, 2, 3, 2:
- Administer diphenhydramine or benztropine
- Occurred in <1-2% in clinical studies 2
Respiratory depression 4:
- More common with concurrent benzodiazepines or opioids
- Have airway management equipment ready
- Consider lower doses when combining with other CNS depressants 1
Additional Dosing Considerations
If additional sedation needed 1:
- May administer additional 1.25 mg doses with caution
- Each additional dose should only be given if potential benefit outweighs risk
- Monitor closely for cumulative effects
- Recent evidence (2017) shows midazolam 5 mg + droperidol 5 mg combination is superior to droperidol 10 mg alone for acute agitation
- When combining with other CNS depressants, reduce droperidol dose 1
Critical Safety Points
- Never use in patients with prolonged baseline QTc
- Avoid in patients on other QT-prolonging medications (Class I/III antiarrhythmics, certain antihistamines, antimalarials, TCAs) 1
- Exercise extreme caution in elderly patients - consider starting with 2.5 mg 4
- Document pre-administration ECG and risk assessment in medical record
- The FDA black box warning exists despite limited evidence of actual cardiac events in therapeutic doses 2